Ten years of infliximab (Remicade®) in clinical practice: The story from bench to bedside

European Journal of Pharmacology

Volumn 623, Issue SUPPL.1, 2009, Pages

  Cornillie, Freddy ^a  

^a Medical Affairs Dept   (Belgium)

Author keywords

Inflammatory bowel disease; Infliximab; Monoclonal antibody; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DISEASE CONTROL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SYNTHESIS; EARLY INTERVENTION; ENTERITIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SPONDYLARTHRITIS; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71549146881     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.023     Document Type: Review

References (30)

1. Antoni C., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G., Schneider U., Furst D., Molitor J., Keystone E., Gladman D., Manger B., Wassenberg S., Weier R., Wallace D., Weisman M., Kalden J., and Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis & Rheumatism 52 (2005) 1227-1236
2. Antoni C., Kavanaugh A., van der Heijde D., Beutler A., Keenan G., Zhou B., Kirkham B., Tutuncu Z., Burmester G., Schneider U., Furst D., Molitor J., Keystone E., Gladman D., Manger B., Wassenberg S., Weier R., Wallace D., Weisman M., Kalden J., and Smolen J. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Journal of Rheumatology 35 (2008) 869-876
3. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M., Sörensen H., Zeidler H., Thriene W., and Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
4. Braun J., Deodhar A., Dijkmans B., Geusens P., Sieper J., Wiliamson P., Xu W., Visvanathan S., Baker D., Goldstein N., van der Heijde D., and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Arthritis & Rheumatism (Arthritis Care & Research) 59 (2008) 1270-1278
5. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'?. Immunology Today 21 (2007) 397-402
6. Derckx B., Taminiau J., Radema S., Stronkhorst A., Wortel C., Tijtgat G., and van Deventer S. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 342 (1993) 173-174
7. Elliot M., Maini R., Feldmann M., Kalden J., Antoni C., Smolen J., Leeb B., Breedveld F., Macfarlane J., Bijl H., and Woody J. Randomized double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
8. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14 (1996) 397-440
9. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P., and the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
10. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough D., Scallon B., Arevalo Moore M., Vilcek J., Daddona P., and Grayeb J. Construction and initial characterization of a mouse-human chimaeric anti-TNF antibody. Molecular Immunology 30 (1993) 1443-1453
11. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
12. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D.A., Macfarlane J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N., Schaible T.F., and Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism 4 (1998) 1552-1563
13. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., St.Clair E.W., Keenan G.F., van der Heijde D., Marsters P.A., Lipsky P.E., and for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis & Rheumatism 50 (2004) 1051-1065
14. Maser E.A., Villela R., Silverberg M.S., and Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clinical Gastroenterology and Hepatology 4 (2006) 1248-1254
15. Oh C.J., Das K.M., and Gottlieb A.B. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. Journal of the American Academy of Dermatology 42 (2000) 829-830
16. Present D., Rutgeerts P., Targan S., Hanauer S., Mayer L., van Hogezand R., Podolsky D., Sands B., Braakman T., DeWoody K., Schaible T., and van Deventer S. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine 340 (1999) 1398-1405
17. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., Li S., Dooley L.T., Griffiths C.E.M., and for the EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
18. Rutgeerts P., Feagan B., Lichtenstein G., Mayer L., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D., Olson A., Bao W., and Hanauer S. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
19. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.C., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D.C., Marsters P.A., Travers S.B., Blank M.A., and van Deventer S.J. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine 350 (2004) 876-885
20. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., Van Steen K., Vermeire S., and Rutgeerts P. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58 (2009) 492-500
21. Shen C., Maerten P., Geboes K., van Assche G., Rutgeerts P., and Ceuppens J.L. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clinical Immunology 115 (2005) 250-259
22. St.Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., Keystone E., Schiff M., Kalden J.R., Wang B., DeWoody K., Weiss R., Baker D., and for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis a randomized, controlled trial. Arthritis & Rheumatism 50 (2004) 3432-3443
23. Targan S., Hanauer S., van Deventer S., Mayer L., Present D., Braakman T., DeWoody K., Schaible T., and Rutgeerts P. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. New England Journal of Medicine 337 (1997) 1029-1035
24. van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., Ternant D., Watier H., Paintaud G., and Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 (2008) 1861-1868
25. van den Bosch F., Kruithof E., de Vos M., de Keyser F., and Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNFα blockade with infliximab on articular symptoms. Lancet 356 (2000) 1821-1822
26. Van den Brande J.M.H., Koehler T., Zelinkova Z., Bennink R.J., Hommes D.W., te Velde A.A., Ten Kate F., van Deventer S.J., and Peppelenbosch M.P. Prediction of anti-TNF clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. GUT 56 (2007) 509-517
27. van der Kooij S.M., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Güler-Yüksel M., Zwinderman A.H., Kerstens P.J., van der Lubbe P.A., de Beus W.M., Grillet B.A., Ronday H.K., Huizinga T.W., Breedveld F.C., Dijkmans B.A., and Allaart C.F. Drug-free remission, functioning and radiographic rheumatoid arthritis treatment in patients with recent-onset damage after 4 years of response-driven. Annals of the Rheumatic Diseases 68 (2009) 914-921
28. van Dullemen H., van Deventer S., Hommes D., Bijl H., Jansen J., Tytgat G., and Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 (1995) 129-135
29. Vastesaeger N., Xu S., Aletaha D., St Clair E.W., and Smolen J.S. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology 48 (2009) 1114-1121
30. Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., Rahman M.U., and for the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. A large, randomized, placebo-controlled trial. Arthritis & Rheumatism 54 (2006) 1075-1086